Iterum <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Extension and Increased Interest Rate on Promissory Note with Pfizer
Iterum Therapeutics plc, a company dedicated to developing next-generation antibiotics, announced an extension of the term of their $20 million promissory note owed to Pfizer Inc. The due date for this regulatory milestone payment, associated with the FDA approval of ORLYNVAH™, has been extended from October 2026 to October 2029. In connection with this extension, the annual interest rate on the note will increase from 8% to 10% starting in October 2026. This extension allows Iterum to strategically invest capital from ORLYNVAH™ sales to support its market launch and expansion efforts.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iterum Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-073950), on May 19, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。